© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#bone mineral density

Even With New, Bone-Friendly HIV Regimens, More Bone Research Is Needed

This is especially the case for people globally who don’t have access to such newer regimens.

What’s the Skinny on Bone Health for People With HIV?

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

Testosterone Use Is Tied to Higher Bone Density in Men With HIV

More research is needed to determine the potential risks and benefits of testosterone treatment in this population.

The Liver Meeting 2018 Roundup

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Switching to Janssen’s Symtuza Is Safe and Effective Up to 96 Weeks

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

FDA Approves Janssen’s Symtuza for HIV Treatment

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

In the HIV Population, Bone Loss Is Greater Among Women

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

Janssen’s Experimental Symtuza Performs Well in Those New to HIV Meds

A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.

Gilead’s Updated Version of Tenofovir Performs Well Among Blacks With HIV

Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.

Treatment: Bone Loss

Those who start antiretroviral (ARV) treatment for HIV soon after diagnosis experience a greater decline in bone mineral density.

New Tenofovir Improves Markers of Kidney and Bone Health in Older People

HIV-positive people 50 and older who switched from Truvada to Descovy in a recent trial reaped health benefits.

More Evidence That Updated Tenofovir Is Safer to Bones and Kidneys

Gilead Sciences has released results from three studies examining the effects of switching from the old tenofovir to the new version.

Is Bone Density Loss on PrEP Higher Than Previously Believed?

Previous research on bone loss during the first year on PrEP may have failed to consider poor adherence to the regimen.

PrEP Use May Stunt Bone Growth in Young Men

After losing bone density during a year on PrEP, young men recouped their losses a year later but didn’t catch up with norms.

FDA OKs Gilead’s Descovy, a Safer Version of Truvada, for HIV Treatment Only (Not for PrEP)

The FDA has approved Gilead Sciences’ fixed-dose combination tablet Descovy (emtricitabine/tenofovir alafenamide) for HIV treatment.

Starting HIV Treatment Earlier Translates to More Bone Loss

Those who begin HIV treatment soon after diagnosis experience more bone loss than those who defer taking antiretrovirals until HIV disease has...
Advertisement